These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3161000)

  • 1. Pulmonary toxicity of monocrotaline differs at critical periods of lung development.
    Todd L; Mullen M; Olley PM; Rabinovitch M
    Pediatr Res; 1985 Jul; 19(7):731-7. PubMed ID: 3161000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperoxia-induced pulmonary vascular and lung abnormalities in young rats and potential for recovery.
    Wilson WL; Mullen M; Olley PM; Rabinovitch M
    Pediatr Res; 1985 Oct; 19(10):1059-67. PubMed ID: 2932674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response relationship in intoxication by the pyrrolizidine alkaloid monocrotaline.
    Shubat PJ; Hubbard AK; Huxtable RJ
    J Toxicol Environ Health; 1989; 28(4):445-60. PubMed ID: 2531804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of methylprednisolone on monocrotaline-induced pulmonary vascular disease and right ventricular hypertrophy.
    Langleben D; Reid LM
    Lab Invest; 1985 Mar; 52(3):298-303. PubMed ID: 3156262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary vasculature in monocrotaline-induced hypertensive rats on magnesium therapy.
    Mathew R; Gloster ES; Altura BT; Altura BM
    Microcirc Endothelium Lymphatics; 1990; 6(4-5):267-83. PubMed ID: 2149161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. A biochemical and ultrastructural study.
    Todorovich-Hunter L; Johnson DJ; Ranger P; Keeley FW; Rabinovitch M
    Lab Invest; 1988 Feb; 58(2):184-95. PubMed ID: 3123799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strain differences in pulmonary hypertensive response to monocrotaline alkaloid and the beneficial effect of oral magnesium treatment.
    Mathew R; Altura BT; Altura BM
    Magnesium; 1989; 8(2):110-6. PubMed ID: 2526910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ventilatory dysfunction precedes pulmonary vascular changes in monocrotaline-treated rats.
    Lai YL; Olson JW; Gillespie MN
    J Appl Physiol (1985); 1991 Feb; 70(2):561-6. PubMed ID: 1902454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocrotaline-induced angiogenesis. Differences in the bronchial and pulmonary vasculature.
    Schraufnagel DE
    Am J Pathol; 1990 Nov; 137(5):1083-90. PubMed ID: 1700616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of various doses of monocrotaline administration on the development of pulmonary hypertension and its regression in rats].
    Kakusaka I; Kaneko N; Kiyatake K; Fujita A; Suzuki A; Nakano K; Okada O; Sugita T; Watanabe S; Kuriyama T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Jan; 27(1):51-6. PubMed ID: 2501548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole.
    Schultze AE; Roth RA
    Toxicol Appl Pharmacol; 1993 Jul; 121(1):129-37. PubMed ID: 7687795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
    Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
    Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats.
    Sugita T; Hyers TM; Dauber IM; Wagner WW; McMurtry IF; Reeves JT
    J Appl Physiol Respir Environ Exerc Physiol; 1983 Feb; 54(2):371-4. PubMed ID: 6219974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum copper concentration as an index of cardiopulmonary injury in monocrotaline-treated rats.
    Molteni A; Ward WF; Ts'ao CH; Fitzsimons EJ
    Ann Clin Lab Sci; 1988; 18(6):476-83. PubMed ID: 3149170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supplemental oxygen reduces right ventricular hypertrophy in monocrotaline-injected rats.
    Hill NS; Jederlinic P; Gagnon J
    J Appl Physiol (1985); 1989 Apr; 66(4):1642-8. PubMed ID: 2525121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
    Ganey PE; Sprugel KH; Hadley KB; Roth RA
    J Pharmacol Exp Ther; 1986 Apr; 237(1):226-31. PubMed ID: 2937908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension.
    Kay JM; Keane PM; Suyama KL; Gauthier D
    Thorax; 1982 Feb; 37(2):88-96. PubMed ID: 6281933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease.
    Todorovich-Hunter L; Dodo H; Ye C; McCready L; Keeley FW; Rabinovitch M
    Am Rev Respir Dis; 1992 Jul; 146(1):213-23. PubMed ID: 1626806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrin thrombosis in monocrotaline pyrrole-induced cor pulmonale in rats.
    Lalich JL; Johnson WD; Raczniak TJ; Shumaker RC
    Arch Pathol Lab Med; 1977 Feb; 101(2):69-73. PubMed ID: 138406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension.
    Langleben D; Carvalho AC; Reid LM
    Am Rev Respir Dis; 1986 May; 133(5):789-91. PubMed ID: 3085563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.